Euan Murray

2.3k total citations
44 papers, 1.9k citations indexed

About

Euan Murray is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Euan Murray has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 8 papers in Cell Biology and 7 papers in Oncology. Recurrent topics in Euan Murray's work include Endoplasmic Reticulum Stress and Disease (8 papers), Inflammatory mediators and NSAID effects (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Euan Murray is often cited by papers focused on Endoplasmic Reticulum Stress and Disease (8 papers), Inflammatory mediators and NSAID effects (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Euan Murray collaborates with scholars based in United States, United Kingdom and Czechia. Euan Murray's co-authors include Steven Clarke, William J. Wechter, Darko Kantoci, Ted R. Hupp, Randy Robinson, Bořivoj Vojtěšek, Brett A. Johnson, Dana W. Aswad, David B. Glass and Ingegerd Hellström and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Euan Murray

44 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Euan Murray United States 22 1.0k 344 315 297 230 44 1.9k
J. Oliver McIntyre United States 27 1.1k 1.0× 343 1.0× 247 0.8× 118 0.4× 124 0.5× 68 2.2k
Vincent C.O. Njar United States 37 2.2k 2.2× 531 1.5× 156 0.5× 119 0.4× 787 3.4× 125 4.4k
Edward A. Bump United States 28 1.5k 1.5× 431 1.3× 358 1.1× 81 0.3× 166 0.7× 55 2.8k
Robert‐Alain Toillon France 27 1.4k 1.4× 873 2.5× 125 0.4× 159 0.5× 261 1.1× 54 2.5k
Amanda F. Baker United States 32 1.6k 1.5× 606 1.8× 255 0.8× 120 0.4× 206 0.9× 56 2.7k
Lars Öhman United States 10 1.6k 1.5× 475 1.4× 123 0.4× 79 0.3× 338 1.5× 12 3.4k
Anait S. Levenson United States 32 1.9k 1.8× 638 1.9× 103 0.3× 101 0.3× 211 0.9× 63 3.1k
Anthony M. Treston United States 25 1.3k 1.3× 532 1.5× 61 0.2× 114 0.4× 273 1.2× 79 2.6k
Hyun Seung Ban South Korea 30 1.5k 1.4× 323 0.9× 409 1.3× 146 0.5× 474 2.1× 92 2.6k
Rosanna Paciucci Spain 25 1.7k 1.7× 540 1.6× 49 0.2× 241 0.8× 122 0.5× 43 2.8k

Countries citing papers authored by Euan Murray

Since Specialization
Citations

This map shows the geographic impact of Euan Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Euan Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Euan Murray more than expected).

Fields of papers citing papers by Euan Murray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Euan Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Euan Murray. The network helps show where Euan Murray may publish in the future.

Co-authorship network of co-authors of Euan Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Euan Murray. A scholar is included among the top collaborators of Euan Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Euan Murray. Euan Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mohtar, M. Aiman, Lenka Hernychová, J. Robert O’Neill, et al.. (2018). The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM. Molecular & Cellular Proteomics. 17(4). 737–763. 17 indexed citations
2.
Jain, Saurabh, Luca Aresu, S. Comazzi, et al.. (2016). The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLoS ONE. 11(2). e0148366–e0148366. 78 indexed citations
3.
Clarke, David J., Euan Murray, Jakub Faktor, et al.. (2016). Mass spectrometry analysis of the oxidation states of the pro-oncogenic protein anterior gradient-2 reveals covalent dimerization via an intermolecular disulphide bond. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1864(5). 551–561. 15 indexed citations
4.
Murray, Euan, et al.. (2014). Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2. Molecular BioSystems. 10(6). 1409–1425. 15 indexed citations
5.
Hrstka, Roman, Euan Murray, Veronika Brychtová, et al.. (2013). Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters. 333(2). 187–193. 23 indexed citations
6.
Chevet, Éric, Delphine Fessart, Frédéric Delom, et al.. (2012). Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene. 32(20). 2499–2509. 121 indexed citations
7.
MacLaine, Nicola J., Caroline O. Michie, Pavla Bouchalová, et al.. (2012). Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. Journal of Immunological Methods. 378(1-2). 20–32. 42 indexed citations
8.
Hrstka, Roman, Rudolf Nenutil, Magdalena M. Maslon, et al.. (2010). The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 29(34). 4838–4847. 84 indexed citations
9.
Leipold, Douglas D., et al.. (2004). Bioinversion of R‐flurbiprofen to S‐flurbiprofen at various dose levels in rat, mouse, and monkey. Chirality. 16(6). 379–387. 22 indexed citations
10.
Wechter, William J., et al.. (2000). Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofen. Life Sciences. 66(8). 745–753. 55 indexed citations
11.
Wechter, William J. & Euan Murray. (1998). Has the Elusive ‘Natriuretic Factor’ Been Discovered, and If So, Is It a Hormone?. Nephron Experimental Nephrology. 6(6). 488–490. 7 indexed citations
12.
Wechter, William J., et al.. (1996). A new endogenous natriuretic factor: LLU-alpha.. Proceedings of the National Academy of Sciences. 93(12). 6002–6007. 156 indexed citations
13.
Wechter, William J., et al.. (1996). Antiproliferative Effects of the Enantiomers of Flurbiprofen. The Journal of Clinical Pharmacology. 36(6). 540–545. 50 indexed citations
14.
Murray, Euan, Darko Kantoci, Derin C. D’Amico, et al.. (1995). Endogenous natriuretic factors 3: isolation and characterization of human natriuretic factors llu-α, LLU-β1, and llu-γ. Life Sciences. 57(23). 2145–2161. 16 indexed citations
15.
Murray, Euan, et al.. (1995). Natriuretic hormones II. Birkhäuser Basel eBooks. 45. 245–288. 6 indexed citations
16.
Wechter, William J., et al.. (1994). Chiral pharmacokinetics of rac‐flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Chirality. 6(6). 457–459. 7 indexed citations
17.
Murray, Euan, et al.. (1993). Endogenous natriuretic factors 1: Sodium pump inhibition does not correlate with natriuretic or pressor activities from uremic urine. Life Sciences. 52(12). 1045–1054. 8 indexed citations
18.
Murray, Euan, et al.. (1993). Rac‐Flurbiprofen is more ulcerogenic than its (S)‐enantiomer. Chirality. 5(7). 492–494. 49 indexed citations
19.
Levine, Barry H., et al.. (1993). Endogenous natriuretic factors. 2: Characterization of natriuretic and vasopressive substances from human uremic urine.. PubMed. 22 Suppl 2. S63–8. 4 indexed citations
20.
Robinson, Randy, et al.. (1987). Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.. The Journal of Immunology. 139(10). 3521–3526. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Oliver McIntyre Breakdown of academic impact, for papers by Vincent C.O. Njar Breakdown of academic impact, for papers by Edward A. Bump Breakdown of academic impact, for papers by Robert‐Alain Toillon Breakdown of academic impact, for papers by Amanda F. Baker Breakdown of academic impact, for papers by Lars Öhman Breakdown of academic impact, for papers by Anait S. Levenson Breakdown of academic impact, for papers by Anthony M. Treston Breakdown of academic impact, for papers by Hyun Seung Ban Breakdown of academic impact, for papers by Rosanna Paciucci
Rankless by CCL
2026